As of 2:30 PM on the 21st, Celltrion Healthcare is trading at 87,500 KRW, up 0.92% from the previous day. The trading volume is 556,076 shares, which is about 37.63% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.
On October 20th, Kiwoom Securities researchers Hyemin Heo and Kyunghwan Kim stated, "Interim data from Phase 2/3 clinical trials of the COVID-19 treatment are expected to be announced within the year, and based on the results, an application for emergency use authorization in Korea is anticipated. The market penetration of Remsima SC will affect the margin improvement, so the penetration speed of Remsima SC in 2021 will be a key point to watch. The company's profit-sharing for the COVID-19 treatment is higher than that of existing biosimilars, and since it is responsible for global sales, if successful, it is expected to be the first global launch of a new drug rather than a biosimilar or biobetter." They set the target price for Celltrion Healthcare at 130,000 KRW.
Over the past five days, individual investors have net purchased 478,814 shares of Celltrion Healthcare, while foreign investors and institutions have net sold 35,867 shares and 451,614 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
